MK-2060 clinical trials
Also written MK-2060.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses MK-2060 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MK-2060
- 7
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses MK-2060 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)CompletedPhase 2Merck Sharp & Dohme LLCNCT05027074Written as MK-2060
- A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT05656040Written as MK-2060
- A Study of MK-2060 in Healthy Participants (MK-2060-016)CompletedPhase 1Merck Sharp & Dohme LLCNCT06582602Written as MK-2060
- Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)CompletedPhase 1Merck Sharp & Dohme LLCNCT05769595Written as MK-2060
- Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06843993Written as MK-2060
- MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)CompletedPhase 1Merck Sharp & Dohme LLCNCT05335005Written as MK-2060
- Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)CompletedPhase 1Merck Sharp & Dohme LLCNCT03873038Written as MK-2060